SACRAMENTO, Calif.--(BUSINESS WIRE)--Nivagen Pharmaceuticals, Inc. (“Nivagen”), a specialty pharmaceuticals company, announced the sale of its MedisourceRx business unit to the leading health and wellness company, Hims & Hers Health, Inc, with Bourne Partners as its exclusive financial advisor.

加利福尼亚州萨克拉门托——（商业新闻短讯）——专业制药公司尼瓦根制药有限公司（“尼瓦根”）宣布将其MedisourceRx业务部门出售给领先的健康与保健公司Hims＆Hers health，Inc.，Bourne Partners为其独家财务顾问。

The MedisourceRx business unit is an FDA registered 503B outsourcing facility. The proceeds from the sale will be used to complete the build out of a 100,000 square foot state-of-the-art sterile manufacturing and R&D facility which will enable Nivagen to onshore its production capabilities and enter the CDMO business.

MedisourceRx业务部门是FDA注册的503B外包设施。出售所得将用于完成10万平方英尺最先进的无菌生产和研发设施的建设，这将使尼瓦根能够在陆上拥有生产能力并进入CDMO业务。

By reshoring sterile product manufacturing, Nivagen will streamline its supply chain while significantly reducing both manufacturing costs and time to market for new product launches..

通过重新安排无菌产品制造，尼瓦根将简化其供应链，同时大大降低制造成本和新产品上市时间。。

“In a strategic move, Nivagen has sold its subsidiary, Seaview Enterprises LLC, dba MedisourceRx, an FDA-registered 503B sterile compounding pharmacy in California. The proceeds from this sale will enable Nivagen to sharpen its focus on its upcoming state-of-the-art sterile injectable manufacturing facility in Sacramento,” said Jay Shukla, CEO of Nivagen.

Nivagen首席执行官Jay Shukla表示：“作为一项战略举措，Nivagen出售了其子公司Seaview Enterprises LLC，dba MedisourceRx，这是一家在加利福尼亚州注册的503B无菌复合药房。此次出售的收益将使Nivagen能够将重点放在即将在萨克拉门托建立的最先进的无菌注射生产设施上。”。

“Additionally, the move will allow Nivagen to focus on the ANDAs and 505(b)(2) pipeline, further advancing its growth strategy.”.

“此外，此举将使尼瓦根能够专注于ANDAs和505（b）（2）管道，进一步推进其增长战略。”。

About Nivagen Pharmaceuticals, Inc.

关于Nivagen Pharmaceuticals，Inc。

Nivagen (www.nivagen.com) is a specialty pharmaceuticals company engaged in developing, manufacturing, and marketing pharmaceutical products across generics and specialty drugs (including sterile injectables – IV bags, vials, PFS and cartridges) and 505(b)(2)s, as well as offering 503B compounding services to the institutional channel.

Nivagen（www.Nivagen.com）是一家专业制药公司，致力于开发，制造和销售仿制药和特种药物（包括无菌注射剂-静脉注射袋，小瓶，PFS和卡式瓶）和505（b）（2）s的药品，并为机构渠道提供503B复合服务。

The company has a state-of-the-art sterile manufacturing facility that can produce various dosage forms, including sterile IV bags (both aseptic and terminally sterilized) and sterile injectables (including Vial, PFS & Cartridge). The company also has a global distribution network that can reach over 50 countries.

该公司拥有最先进的无菌生产设施，可以生产各种剂型，包括无菌IV袋（无菌和终末灭菌）和无菌注射剂（包括小瓶，PFS和卡式瓶）。该公司还拥有全球分销网络，可覆盖50多个国家。

The company’s vision is to provide high-quality and affordable pharmaceutical products to customers and patients worldwide..

该公司的愿景是为全球客户和患者提供高质量且价格合理的药品。。

About Bourne Partners

关于Bourne Partners

Bourne Partners is a financial services firm specializing in the healthcare, pharma, and pharma services sectors. Located in Charlotte, North Carolina, the company offers investment banking and advisory services. As owners and operators with over 20 years of experience, Bourne Partners strives to enrich the lives and improve the health and well-being of their partners and patients across the globe by facilitating the efficient movement of capital through the global healthcare sector.

Bourne Partners是一家专门从事医疗保健、制药和制药服务行业的金融服务公司。该公司位于北卡罗莱纳州夏洛特，提供投资银行和咨询服务。作为拥有20多年经验的所有者和运营商，Bourne Partners致力于通过促进全球医疗保健部门的资本有效流动，丰富全球合作伙伴和患者的生活，改善他们的健康和福祉。

For more information, please visit here..

有关更多信息，请访问此处。。